falsefalse

ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer - Episode 1

Overview of PD-L1 Testing in Advanced NSCLC

, ,

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Overview of PD-L1 Testing in Advanced NSCLC
    EP. 2: Subgrouping Patients with Advanced NSCLC for Tailored Treatment
    EP. 3: CTLA-4 Targeted Regimens in Advanced NSCLC
    EP. 4: Updates in Gender-Based Treatment for Patients with Advanced NSCLC
    EP. 5: Data Updates on Single-Agent Immunotherapy in Advanced NSCLC
    EP. 6: Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC
    EP. 7: Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC
    EP. 8: Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial
    EP. 9: Combination Chemotherapy and Immunotherapy for Advanced NSCLC
    EP. 10: The Evolution of Chemoimmunotherapy in Advanced NSCLC

    Sponsored in part by Regeneron. Content independently created by OncLive.

    Related Content:

    ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung CancerLung CancerImmunotherapy in Lung CancerOncLive Peer Exchange®
    The OncFive: Top Oncology Articles for the Week of 5/11
    Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases
    European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC
    x